ALBI and PALBI Scores and HCC Prognosis

N/ACompletedNCT05720195

Sohag University645 enrolled

Overview

To compare the predictive ability of ALBI and PALBI grades with CTP and MELD scores. To investigate the efficacy of ALBI and PALBI grades for predicting the prognosis of HCC and overall survival among different modalities of treatment.

Study Type

OBSERVATIONAL

Enrollment

645

Conditions

Hepatocellular Carcinoma (HCC) Prognosis

Interventions

ALBIDIAGNOSTIC_TEST

Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades for prognosis of HCC

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: • The diagnosis of HCC will be based on the presence of an arterial hypervascular focal lesion \> 2 cm with rapid wash-out with a single imaging modality (triphasic computed tomography (CT), or dynamic magnetic resonance imaging (MRI)) or two imaging modalities demonstrating the before mentioned feature for lesions \< 2 cm with or without elevated serum alpha-fetoprotein (AFP) levels. Exclusion Criteria: * Patients below 18 years old. * Patients with pre-existing other malignancies. * Patients with pre-existing gall bladder stones, benign strictures, or other biliary diseases. * Patients with pre-existing haematologic disorders. * Patients with proteinuria. * Missed follow-up.

Locations (1)

Sohag University

Sohag, Egypt

Outcomes

Primary Outcomes

Overall survival among HCC patients as assessed by the albumin-bilirubin (ALBI) score

We will compare the ability of ALBI score to predict overall survival among HCC patients versus Child Pugh and MELD scores

Time frame: 2 years

Overall survival among HCC patients as assessed by the platelet-albumin-bilirubin (PALBI) score

We will compare the ability of PALBI score to predict overall survival among HCC patients versus Child Pugh and MELD scores

Time frame: 2 years

Secondary Outcomes

Overall survival among HCC patients according to treatment modality as assessed by the albumin-bilirubin (ALBI) score

We will compare the ability of ALBI score to predict overall survival among HCC patients stratified according to treatment modality (Surgical resection, local ablation, trans-arterial chemoembolization, sorafenib and best supportive care)

Time frame: 2 years

Overall survival among HCC patients according to treatment modality as assessed by the platelet-albumin-bilirubin (PALBI)

We will compare the ability of PALBI score to predict overall survival among HCC patients stratified according to treatment modality (Surgical resection, local ablation, trans-arterial chemoembolization, sorafenib and best supportive care)

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.